2023 World Conference on Lung Cancer (Posters)-P2.17. Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer

P2.17. Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This scientific presentation at the WCLC 2023 conference focused on the recent treatment patterns and overall survival outcomes in patients with small cell lung cancer (SCLC) who received PD-L1 inhibitors as their first-line therapy. The study analyzed data from a US-based electronic health record database and included patients who initiated systemic therapy for SCLC between 2013 and 2021.<br /><br />Among the 9,660 patients with SCLC included in the study, 82% received systemic therapy and 7,230 initiated first-line therapy. Of those who received first-line therapy, 41% went on to receive second-line therapy, and 17% received third-line therapy. The majority of patients (98%) were smokers, and 66% had extensive-stage disease.<br /><br />The use of PD-L1-based treatment as first-line therapy increased significantly from 7% in 2018 to 80% in 2021 among patients with extensive-stage disease. Maintenance therapy was used in 62% of these patients. The most common second-line treatment prior to 2018 was single-agent topotecan (28%), but it decreased to 6% in 2021. Single-agent lurbinectedin was the most common second-line treatment in 2021 (47%). In third-line therapy, single-agent lurbinectedin (31%) or topotecan (24%) were the most common treatments in 2021.<br /><br />The median real-world overall survival after first-line therapy was 8.5 months for patients treated with PD-L1 inhibitors and 8.1 months for those who did not receive a PD-L1 inhibitor. The 12-month overall survival was 34.1% in the PD-L1 group and 29.1% in the non-PD-L1 group. Younger age and better performance status were associated with longer survival in both groups.<br /><br />The study concluded that while there have been significant changes in treatment patterns for SCLC in the past four years, overall survival outcomes after progression on first-line therapy remain sub-optimal regardless of prior immunotherapy. The authors emphasized the need for novel approaches to improve outcomes for this patient population.

Asset Subtitle

Hossein Borghaei

Meta Tag

Speaker Hossein Borghaei

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

scientific presentation

WCLC 2023 conference

treatment patterns

overall survival outcomes

small cell lung cancer

SCLC

PD-L1 inhibitors

first-line therapy

systemic therapy

electronic health record database